CONGRESS|#EHA2021| Stefania Oliva, University of Torino, debated & favored the idea about tailoring treatment based on minimal residual disease in MM. #mmsm, #myeloma pic.twitter.com/g2ifhKzk08

— Multiple Myeloma Hub (@MM_Hub) June 14, 2021